Top

Published in:

01-02-2009 | Case Report

Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis

Authors: Kyoung-Hwa Choi, Wan-Hee Yoo

Published in: Rheumatology International | Issue 4/2009

Abstract

We first report a case of patient with refractory dermatomyositis (DM) who successfully treated with tumor necrosis factor-α blocker, etanercept and developed necrotizing fasciitis (NF) after the use of it. NF was diagnosed early by MRI and managed with antimicrobial therapy and timely debridement of necrotic tissue with favorable outcome. We suggest that etanercept can be a useful therapeutic agent in patients with DM refractory to steroid and immunosuppressive agents and NF may occur in DM in association with etanercept therapy. We also suggest that management strategies for early diagnosis and treatment are needed for this complication.

Callen JP (2000) Dermatomyositis. Lancet 355:53–57. doi:10.1016/S0140-6736(99)05157-0 PubMedCrossRef

Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83:35–42. doi:10.1097/01.md.0000109755.65914.5e CrossRef

Sprott H, Glatzel M, Michel BA (2004) Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 43:524–526. doi:10.1093/rheumatology/keh062 CrossRef

Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50:10–15. doi:10.1159/000070852 PubMedCrossRef

Hengstman GJ, van den Hoogen FH, van Engelen BG (2004) Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: longterm follow-up. Eur Neurol 52:61–63. doi:10.1159/000079547 PubMedCrossRef

Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65:1233–1236. doi:10.1136/ard.2005.048744 PubMedCrossRef

Maynor M, Kardon E, Talavera F, Weiss E, Halamaka J, Feied C Necrotizing fasciitis. eMedicine. Available at http://www.emedicine.com/emerg/topic332.htm. [Accessed 12 May 2005]

McEntegart A, Capell HA (2002) Necrotizing fasciitis in a patient with rheumatoid arthritis. Rheumatology (Oxford) 41:828–829. doi:10.1093/rheumatology/41.7.828 CrossRef

Hashimoto N, Sugiyama H, Asagoe K, Hara K, Yamasaki O, Yamasaki Y et al (2002) Fulminant necrotising fasciitis developing during long term corticosteroid treatment of systemic lupus erythematosus. Ann Rheum Dis 61:848–849. doi:10.1136/ard.61.9.848 PubMedCrossRef

10.

Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H et al (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53:155–165. doi:10.1002/art.21083 PubMedCrossRef

11.

Lundberg IE, Dastmalchi M (2002) Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 28:799–822. doi:10.1016/S0889-857X(02)00025-X PubMedCrossRef

12.

Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM et al (2000) TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43:2368–2377. doi:10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8PubMedCrossRef

13.

Tateyama M, Nagano I, Yoshioka M, Chida K, Nakamura S, Itoyama Y (1997) Expression of tumor necrosis factor-alpha in muscles of polymyositis. J Neurol Sci 146:45–51. doi:10.1016/S0022-510X(96)00280-8 PubMedCrossRef

14.

Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, International Myositis Assessment and Clinical Studies Group et al (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–2615. doi:10.1002/art.21291 PubMedCrossRef

15.

Weinblatt ME, Kremer JM, Bankurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259. doi:10.1056/NEJM199901283400401 PubMedCrossRef

16.

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593. doi:10.1056/NEJM200011303432201 PubMedCrossRef

17.

Chan AT, Cleeve V, Daymond TJ (2002) Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78:47–48. doi:10.1136/pmj.78.915.47 PubMedCrossRef

18.

Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41:22–26. doi:10.1093/rheumatology/41.1.22 CrossRef

19.

Jarrett P, Rademaker M, Duffill M (1997) The clinical spectrum of necrotizing fasciitis. A review of 15 cases. Aust N Z J Med 27:29–34PubMed

Title: Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis
Authors: Kyoung-Hwa Choi
Wan-Hee Yoo
Publication date: 01-02-2009
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 4/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0695-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Is leptin a significant predictor of bone mineral density in postmenopausal Turkish women?

Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling

Targeting the CD134–CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis

Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis

Ischiogluteal bursitis: a report of three cases with MR findings

Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page